Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies

References

• Littlejohn EA, Monrad SU. Early diagnosis and treatment of rheumatoid arthritis. Prim Care. 2018 Jun;45(2):237–255. doi: 10.1016/j.pop.2018.02.010
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018 Oct 2;320(13):1360–1372.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Atzeni F, Balsa A, et al. The key comorbidities in patients with rheumatoid arthritis: a narrative review. J Clin Med. 2021 Feb 1;10(3):509.
   PubMed Web of Science ®Google Scholar
• Nair S, Singh Kahlon S, Sikandar R, et al. Tumor necrosis factor-alpha inhibitors and cardiovascular risk in rheumatoid arthritis: a systematic review. Cureus. 2022 Jun;14(6):e26430. doi: 10.7759/cureus.26430
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bergstra SA, et al. Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis. Ann Rheumatic Dis. 2022;82(4):ard-2022–223356. doi: 10.1136/ard-2022-223443
   Web of Science ®Google Scholar
• Navarro F, Martinez-Sesmero JM, Balsa A, et al. Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain. Clin Rheumatol. 2020 Oct;39(10):2919–2930. doi: 10.1007/s10067-020-05087-3
   PubMed Web of Science ®Google Scholar
• Benjamin O, Goyal A, Lappin SL. Disease modifying anti-rheumatic drugs (DMARD) StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Sep]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507863/
   Google Scholar
• Stevenson M, Archer R, Tosh J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess. 2016 Apr;20(35):1–610.
   Web of Science ®Google Scholar
• Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1–229. doi: 10.3310/hta10420
   PubMed Web of Science ®Google Scholar
• Lekander I, Borgström F, Lysholm J, et al. The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice. Eur J Health Econ. 2013;14(6):863–873. doi: 10.1007/s10198-012-0431-6
   PubMed Web of Science ®Google Scholar
• Gissel C, Gotz G, Repp H. Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany. Z Rheumatol. 2016 Dec;75(10):1006–1015. doi: 10.1007/s00393-016-0071-9
   PubMed Web of Science ®Google Scholar
• Fatemi B, Rezaei S, Taheri S, et al. Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience. Expert Rev Pharmacoecon Outcomes Res. 2021 Nov 1;21:1–10.
   PubMed Web of Science ®Google Scholar
• Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am j med. 2002 Oct 1;113(5):400–408.
   PubMed Web of Science ®Google Scholar
• Valle-Mercado C, Cubides MF, Parra-Torrado M, et al. Cost-effectiveness of biological therapy compared with methotrexate in the treatment for rheumatoid arthritis in Colombia. Rheumatol Int. 2013 Dec;33(12):2993–2997. doi: 10.1007/s00296-013-2834-9
   PubMed Web of Science ®Google Scholar
• Eriksson JK, Karlsson JA, Bratt J, et al. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. Ann Rheum Dis. 2015 Jun;74(6):1094–1101. doi: 10.1136/annrheumdis-2013-205060
   PubMed Web of Science ®Google Scholar
• Jalal H, O’Dell JR, Bridges SL Jr., et al. Cost-effectiveness of triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016 Dec;68(12):1751–1757. doi: 10.1002/acr.22895
   PubMed Web of Science ®Google Scholar
• Fournier M, Chen CI, Kuznik A, et al. Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient. Clinicoecon Outcomes Res. 2019;11:117–128. doi: 10.2147/CEOR.S183076
   PubMed Web of Science ®Google Scholar
• Lindgren P, Geborek P, Kobelt G. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. Int J Technol Assess Health Care. 2009;25(2):181–189. doi: 10.1017/S0266462309090230
   PubMed Web of Science ®Google Scholar
• Wu B, Wilson A, Wang FF, et al. Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china. PLoS One. 2012;7(10):e47373. doi: 10.1371/journal.pone.0047373
   PubMed Web of Science ®Google Scholar
• Shi ZC, Fei HP, Wang ZL. Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients. Medicine (Baltimore). 2020 Jan;99(3):e16635. doi: 10.1097/MD.0000000000016635
   PubMed Web of Science ®Google Scholar
• Brennan A, Bansback N, Reynolds A, et al. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford). 2004 Jan;43(1):62–72. doi: 10.1093/rheumatology/keg451
   PubMed Web of Science ®Google Scholar
• Li SN, Li JH, Peng LB, et al. Cost-effectiveness of triple therapy vs. Biologic treatment sequence as first-line therapy for rheumatoid arthritis patients after methotrexate failure. Rheumatol Ther. 2021;8(2):775–791. doi: 10.1007/s40744-021-00300-4
   PubMed Web of Science ®Google Scholar
• Alemao E, Johal S, Al MJ, et al. Cost-effectiveness analysis of abatacept compared with adalimumab on background methotrexate in biologic-naive adult patients with rheumatoid arthritis and poor prognosis. Value Health. 2018 Feb;21(2):193–202. doi: 10.1016/j.jval.2017.05.020
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M. PRISMA-P group preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi: 10.1186/2046-4053-4-1
   PubMed Web of Science ®Google Scholar
• Bagepally, BS, Haridoss M. Cost-effectiveness of TNF-alpha inhibitors, B-cell inhibitors and JAK inhibitors for the treatment of rheumatoid arthritis: systematic review and meta-analysis. 2021. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021222541
   Google Scholar
• Center for the Evaluation of Value and Risk in Health. Boston: Institute for Clinical Research and Health Policy Studies, Tufts Medical Center; [cited 2021 May]. Available from: https://cevr.tuftsmedicalcenter.org/databases/cea-registry
   Google Scholar
• Ouzzani MH, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. doi: 10.1186/s13643-016-0384-4
   PubMedGoogle Scholar
• Rohatgi A. WebPlotDigitizer. USA2021.
   Google Scholar
• Bagepally B, Chaikledkaew U, Gurav Y, et al. Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diab Res Care. 2020 Jul 01;8(1):e001020.
   PubMed Web of Science ®Google Scholar
• Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, et al. Meta-analysis of economic evaluation studies: data harmonisation and methodological issues. BMC Health Serv Res. 2022 Feb 15;22(1):202.
   PubMed Web of Science ®Google Scholar
• Noparatayaporn P, Thavorncharoensap M, Chaikledkaew U, et al. Incremental net monetary benefit of bariatric surgery: systematic review and meta-analysis of cost-effectiveness evidences. Obes Surg. 2021 Apr 24;31(7):1–12.
   Web of Science ®Google Scholar
• Bagepally BS, Gurav YK, Anothaisintawee T, et al. Cost utility of sodium-glucose cotransporter 2 inhibitors in the treatment of metformin monotherapy failed type 2 diabetes patients: a systematic review and meta-analysis. Value Health. 2019 Dec;22(12):1458–1469. doi: 10.1016/j.jval.2019.09.2750
   PubMed Web of Science ®Google Scholar
• Paulden M. Why it’s time to abandon the ICER. PharmacoEconomics. 2020 Aug;38(8):781–784. doi: 10.1007/s40273-020-00915-5
   PubMed Web of Science ®Google Scholar
• O’Mahony JF. The limitations of icers in screening interventions and the relative net benefit alternative. Value Health. 2015;18(7):A705. doi: 10.1016/j.jval.2015.09.2644
   Web of Science ®Google Scholar
• Bagepally BS, Sajith Kumar S, Natarajan M, et al. Incremental net benefit of cholecystectomy compared with alternative treatments in people with gallstones or cholecystitis: a systematic review and meta-analysis of cost–utility studies. BMJ Open Gastroenterol. 2022;9(1):e000779. doi: 10.1136/bmjgast-2021-000779
   PubMed Web of Science ®Google Scholar
• Kumar SS, Haridoss M, Venkataraman K, et al. Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: a systematic review and meta-analysis of cost-utility studies [systematic review]. Front Pharmacol. 2022 Dec 13;13:13.
   Web of Science ®Google Scholar
• Sasidharan A, Bagepally BS, Kumar SS, et al. Cost-effectiveness of ezetimibe plus statin lipid-lowering therapy: a systematic review and meta-analysis of cost-utility studies. PLoS One. 2022;17(6):e0264563. doi: 10.1371/journal.pone.0264563
   PubMed Web of Science ®Google Scholar
• Bagepally B, Sasidharan A. Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies. Eur J Clin Pharmacol. 2022 Mar 01;78(3):351–363.
   PubMed Web of Science ®Google Scholar
• Kumar SS, Bagepally BS, Sasidharan A. Cost effectiveness of rituximab therapy for rheumatoid arthritis: a systematic review and meta-analysis of cost-utility studies. Clin Drug Investig. 2023 Jan 09;43(2):97–108.
   PubMed Web of Science ®Google Scholar
• World Bank Country and Lending Groups – World Bank Data Help Desk: The World Bank. 2021 [Cited 2021 18]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups
   Google Scholar
• MicrosoftCorporation. Microsoft excel [Internet]. 2018 [cited 2022 Sep]. Available from: https://office.microsoft.com/excel
   Google Scholar
• StataCorp. Stata Statistical software: Release 16. College Station, TX: StataCorp LLC.; 2019 [cited 2022 Dec 16]. Available from: https://www.stata.com/
   Google Scholar
• vGp AC, Hiligsmann M, SMAA E. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):513–523. doi: 10.1586/14737167.2015.1103185
   PubMed Web of Science ®Google Scholar
• Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clinical Epidemiol. 2011 Apr 01;64(4):383–394.
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Rind D, Akl EA, et al. The GRADE working group clarifies the construct of certainty of evidence. J Clinical Epidemiol. 2017 Jul 01;87:4–13.
   PubMed Web of Science ®Google Scholar
• Bansback N, Phibbs CS, Sun H, et al. Triple therapy versus biologic therapy for active rheumatoid arthritis: a cost-effectiveness analysis. Ann Intern Med. 2017 Jul 4;167(1):8–16.
   PubMed Web of Science ®Google Scholar
• Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis. 2005 Jul;64(7):995–1002. doi: 10.1136/ard.2004.027565
   PubMed Web of Science ®Google Scholar
• Barbieri M, Wong JB, Drummond M. The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. PharmacoEconomics. 2005;23(6):607–618. doi: 10.2165/00019053-200523060-00007
   PubMed Web of Science ®Google Scholar
• Benucci M, Saviola G, Baiardi P, et al. Cost-effectiveness treatment with rituximab in patients with rheumatoid arthritis in real life. Rheumatol Int. 2011 Nov;31(11):1465–1469. doi: 10.1007/s00296-010-1502-6
   PubMed Web of Science ®Google Scholar
• Boyadzieva VV, Stoilov N, Stoilov RM, et al. Quality of life and cost study of rheumatoid arthritis therapy with biological medicines. Front Pharmacol. 2018;9:794. doi: 10.3389/fphar.2018.00794
   PubMed Web of Science ®Google Scholar
• Brennan A, Bansback N, Nixon R, et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British society for rheumatology biologics registry. Rheumatology (Oxford). 2007 Aug;46(8):1345–1354. doi: 10.1093/rheumatology/kem115
   PubMed Web of Science ®Google Scholar
• Brown S, Everett CC, Naraghi K, et al. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technol Assess. 2018 Jun;22(34):1–280. doi: 10.3310/hta22340
   Web of Science ®Google Scholar
• Chen DY, Hsu PN, Tang CH, et al. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan. J Med Econ. 2019 Aug;22(8):777–787. doi: 10.1080/13696998.2019.1606813
   PubMed Web of Science ®Google Scholar
• Claxton L, Taylor M, Gerber RA, et al. Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States. Curr Med Res Opin. 2018 Nov;34(11):1991–2000. doi: 10.1080/03007995.2018.1497957
   PubMed Web of Science ®Google Scholar
• Davies A, Cifaldi MA, Segurado OG, et al. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol. 2009 Jan;36(1):16–26. doi: 10.3899/jrheum.080257
   PubMed Web of Science ®Google Scholar
• Diamantopoulos A, Benucci M, Capri S, et al. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ. 2012;15(3):576–585. doi: 10.3111/13696998.2012.665110
   PubMedGoogle Scholar
• Jessica Barreto DS, da Silva MRR, Almeida AM, et al. Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model. Expert Rev Pharmacoecon Outcomes Res. 2021 Nov 2;21:1–6.
   PubMed Web of Science ®Google Scholar
• Manders SHM, Kievit W, Adang E, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther. 2015 May 22;17(1):134.
   PubMedGoogle Scholar
• Farahani P, Levine M, Goeree R. A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics. J Eval Clin Pract. 2006;12(4):463–470. doi: 10.1111/j.1365-2753.2006.00731.x
   PubMed Web of Science ®Google Scholar
• Ghabri S, Binard A, Pers YM, et al. Economic evaluation of sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis and inadequate response or intolerance to methotrexate in France. Value Health. 2020 Apr;23(4):461–470. doi: 10.1016/j.jval.2019.12.003
   PubMed Web of Science ®Google Scholar
• Hallinen TA, Soini EJ, Eklund K, et al. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology (Oxford). 2010 Apr;49(4):767–777. doi: 10.1093/rheumatology/kep425
   PubMed Web of Science ®Google Scholar
• Meshkini AH, Nikfar S, Glaser E, et al. Cost-effectiveness analysis of tocilizumab in comparison with infliximab in Iranian rheumatoid arthritis patients with inadequate response to tdmards: a multistage Markov Model. Value Health Reg Issues. 2016 May;9:42–48.
   PubMedGoogle Scholar
• Hidalgo-Vega A, Villoro R, Blasco JA, et al. Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain. Cost Eff Resour Alloc. 2015;13(1):11. doi: 10.1186/s12962-015-0037-9
   PubMedGoogle Scholar
• Huoponen S, Aaltonen KJ, Viikinkoski J, et al. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis. PLoS One. 2019;14(7):e0220142. doi: 10.1371/journal.pone.0220142
   PubMed Web of Science ®Google Scholar
• Incerti D, Hern EE, Tkacz J, et al. The effect of dose escalation on the cost-effectiveness of etanercept and adalimumab with methotrexate among patients with moderate to severe rheumatoid arthritis. JMCP. 2020 Oct;26(10):1236–1242. doi: 10.18553/jmcp.2020.26.10.1236
   PubMed Web of Science ®Google Scholar
• Jansen JP, Incerti D, Mutebi A, et al. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. J Med Econ. 2017 Jul;20(7):703–714. doi: 10.1080/13696998.2017.1307205
   PubMed Web of Science ®Google Scholar
• Joensuu JT, Aaltonen KJ, Aronen P, et al. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a register study. Rheumatology (Oxford). 2016 Oct;55(10):1803–1811. doi: 10.1093/rheumatology/kew264
   PubMed Web of Science ®Google Scholar
• Kaczor MP, Wójcik R. An economic analysis of TNF-α antagonists for rheumatoid arthritis in Polish settings. Reumatologia. 2007;45(5):268–275.
   Google Scholar
• Karpes Matusevich AR, Lal LS, Chan W, et al. Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis. JMCP. 2021;27(1):73–83. doi: 10.18553/jmcp.2021.27.1.073
   PubMed Web of Science ®Google Scholar
• Kielhorn A, Porter D, Diamantopoulos A, et al. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Curr Med Res Opin. 2008 Sep;24(9):2639–2650. doi: 10.1185/03007990802321683
   PubMed Web of Science ®Google Scholar
• Kievit W, Van Herwaarden N, Van Den Hoogen FH, et al. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Ann Rheum Dis. 2016;75(11):1939–1944. doi: 10.1136/annrheumdis-2015-208317
   PubMed Web of Science ®Google Scholar
• Kobelt G, Jönsson L, Young A, et al. The cost-effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology. 2003;42(2):326–335. doi: 10.1093/rheumatology/keg107
   PubMed Web of Science ®Google Scholar
• Kobelt G, Lek EI, Lang A, et al. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care. 2011 Jul;27(3):193–200. doi: 10.1017/S0266462311000195
   PubMed Web of Science ®Google Scholar
• Krieckaert CLM, Nair SC, Nurmohamed MT, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis. 2015;74(2):361–368. doi: 10.1136/annrheumdis-2013-204101
   PubMed Web of Science ®Google Scholar
• Kvamme MK, Lie E, Uhlig T, et al. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies. Rheumatology (Oxford). 2015 Jul;54(7):1226–1235. doi: 10.1093/rheumatology/keu460
   PubMed Web of Science ®Google Scholar
• Lee MY, Park SK, Park SY, et al. Cost-effectiveness of tofacitinib in the treatment of moderate to severe rheumatoid arthritis in South Korea. Clin Ther. 2015 Aug;37(8):1662–76 e2. doi: 10.1016/j.clinthera.2015.07.001
   PubMed Web of Science ®Google Scholar
• Lekander I, Borgström F, Svarvar P, et al. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden. Int J Technol Assess Health Care. 2010 Jan;26(1):54–61. doi: 10.1017/S0266462309990596
   PubMed Web of Science ®Google Scholar
• Li J, Wen Z, Cai A, et al. Real-world cost–effectiveness of infliximab for moderate-to-severe rheumatoid arthritis in a medium-sized city of China. J Comp Eff Res. 2017 May;6(3):205–218. doi: 10.2217/cer-2016-0086
   PubMed Web of Science ®Google Scholar
• Lopatina E, Marshall DA, Coupal L, et al. Cost-utility analysis of second-line therapy with rituximab compared to tumour necrosis factor inhibitors in rheumatoid arthritis. Curr Med Res Opin. 2021 Jan;37(1):157–166. doi: 10.1080/03007995.2020.1846172
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Plosker GL. Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis. PharmacoEconomics. 2004;22(16):1071–1095. doi: 10.2165/00019053-200422160-00004
   PubMed Web of Science ®Google Scholar
• Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15(14):1–300. doi: 10.3310/hta15140
   PubMed Web of Science ®Google Scholar
• Merkesdal S, Kirchhoff T, Wolka D, et al. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure. Eur J Health Econ. 2010 Feb;11(1):95–104. doi: 10.1007/s10198-009-0205-y
   PubMed Web of Science ®Google Scholar
• Muszbek N, Proudfoot C, Fournier M, et al. Cost-effectiveness of sarilumab added to methotrexate in the treatment of adult patients with moderately to severely active rheumatoid arthritis who have inadequate response or intolerance to tumor necrosis factor inhibitors. JMCP. 2019;25(11):1268–1280. doi: 10.18553/jmcp.2019.25.11.1268
   PubMed Web of Science ®Google Scholar
• Muszbek N, Proudfoot C, Fournier M, et al. Economic evaluation of sarilumab in the treatment of adult patients with moderately-to-severely active rheumatoid arthritis who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. Adv Ther. 2019;36(6):1337–1357. doi: 10.1007/s12325-019-00946-1
   PubMed Web of Science ®Google Scholar
• Nguyen CM, Bounthavong M, Mendes MA, et al. Cost utility of tumour necrosis factor-alpha inhibitors for rheumatoid arthritis: an application of bayesian methods for evidence synthesis in a Markov model. PharmacoEconomics. 2012 Jul 1;30(7):575–593.
   PubMed Web of Science ®Google Scholar
• Park SK, Park SH, Lee MY, et al. Cost-effectiveness analysis of treatment sequence initiating with etanercept compared with leflunomide in rheumatoid arthritis: impact of reduced etanercept cost with patent expiration in South Korea. Clin Ther. 2016 Nov;38(11):2430–2446 e3. doi: 10.1016/j.clinthera.2016.09.016
   PubMedGoogle Scholar
• Schipper LG, Kievit W, den Broeder AA, et al. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Rheumatology (Oxford). 2011 Jul;50(7):1320–1330. doi: 10.1093/rheumatology/ker084
   PubMed Web of Science ®Google Scholar
• Schlueter M, Finn E, Díaz S, et al. Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain. CEOR. 2019;11:395–403. doi: 10.2147/CEOR.S201621
   Google Scholar
• Schulze-Koops H, Deeg M, Runge C, et al. Health-economic assessment of combination therapy for rheumatoid arthritis with methotrexat and etanercept based on the TEMPO study. Z Rheumatol. 2009 Dec;68(10):836–841. doi: 10.1007/s00393-009-0506-7
   PubMed Web of Science ®Google Scholar
• Soini EJ, Hallinen TA, Puolakka K, et al. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ. 2012;15(2):340–351. doi: 10.3111/13696998.2011.649327
   PubMedGoogle Scholar
• Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-α inhibitors as first-line agents in rheumatoid arthritis. PharmacoEconomics. 2006;24(12):1221–1232. doi: 10.2165/00019053-200624120-00006
   PubMed Web of Science ®Google Scholar
• Stephens S, Botteman MF, Cifaldi MA, et al. Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease. BMJ Open. 2015 Jun 9;5(6):e006560.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Inoue E, Yamaguchi R, et al. Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan. Mod Rheumatol. 2017 Mar;27(2):227–236. doi: 10.1080/14397595.2016.1205799
   PubMed Web of Science ®Google Scholar
• Tanno M, Nakamura I, Ito K, et al. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol. 2006;16(2):77–84. doi: 10.3109/s10165-006-0461-y
   PubMedGoogle Scholar
• Van De Laar CJ, Oude Voshaar MAH, Fakhouri WKH, et al. Cost-effectiveness of a JAK1/JAK2 inhibitor vs a biologic disease-modifying antirheumatic drug (bDMARD) in a treat-to-target strategy for rheumatoid arthritis. Clinicoecon Outcomes Res. 2020;12:213–222. doi: 10.2147/CEOR.S231558
   PubMed Web of Science ®Google Scholar
• van Mulligen E, Weel AE, Kuijper TM, et al. Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial. Ann Rheum Dis. 2020 Dec;79(12):1550–1556. doi: 10.1136/annrheumdis-2020-217528
   PubMed Web of Science ®Google Scholar
• Whittington MD, McQueen RB, Ollendorf DA, et al. Assessing the Value of sarilumab monotherapy for adults with moderately to severely active rheumatoid arthritis: a cost-effectiveness analysis. J Manag Care Spec Pharm. 2019 Jan;25(1):80–87. doi: 10.18553/jmcp.2019.25.1.080
   PubMed Web of Science ®Google Scholar
• Wu B, Song Y, Leng L, et al. Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars. Clin Exp Rheumatol. 2015 Jan;33(1):20–26.
   PubMed Web of Science ®Google Scholar
• Tran-Duy A, Ghiti Moghadam M, Oude Voshaar MAH, et al. An economic evaluation of stopping versus continuing tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients with disease remission or low disease activity: results from a pragmatic Open-label trial. Arthritis & Rheumat. 2018 Jan 1;70(10):1557–1564.
   PubMed Web of Science ®Google Scholar
• Soini E, Asseburg C, Taiha M, et al. Modeled Health economic impact of a hypothetical certolizumab pegol risk-sharing scheme for patients with moderate-to-severe rheumatoid arthritis in Finland. Adv Ther. 2017 Jan 1;34(10):2316–2332.
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Ogale S, Dejonckheere F, et al. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis. Value Health. 2015 Jan 1;18(2):173–179.
   PubMed Web of Science ®Google Scholar
• Chiou CF CJ, Reyes CM, Reyes CM. Cost-effectiveness analysis of biological treatments for rheumatoid arthritis. Expert Review Of Pharmacoeconomics & Outcomes Research. 2004;4(3):307–315. doi: 10.1586/14737167.4.3.307
   PubMedGoogle Scholar
• Patel A, Heslin M, Scott DL, et al. Cost-effectiveness of combination disease-modifying antirheumatic drugs versus tumor necrosis factor inhibitors in active rheumatoid arthritis: a pragmatic, randomized, multicenter trial. Arthritis Care Res (Hoboken). 2020 Mar;72(3):334–342. doi: 10.1002/acr.23830
   PubMed Web of Science ®Google Scholar
• Tzanetakos C, Tzioufas A, Goules A, et al. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece. Rheumatol Int. 2017 Sep;37(9):1441–1452. doi: 10.1007/s00296-017-3736-z
   PubMed Web of Science ®Google Scholar
• Wailoo AJ, Bansback N, Brennan A, et al. Biologic drugs for rheumatoid arthritis in the medicare program: a cost-effectiveness analysis. Arthritis Rheum. 2008 Apr;58(4):939–946. doi: 10.1002/art.23374
   PubMedGoogle Scholar
• Tan C, Luo X, Li S, et al. Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis. Clin Rheumatol. 2022;41(1):63–73. doi: 10.1007/s10067-021-05876-4
   PubMed Web of Science ®Google Scholar
• Tian F, Wen Z, Li J, et al. Cost-effectiveness of anbainuo plus methotrexate compared to conventional disease-modifying antirheumatic drugs for rheumatoid arthritis patients in China. Ann Transl Med. 2021;9(14):1165–1165. doi: 10.21037/atm-21-3132
   PubMed Web of Science ®Google Scholar
• Kuwana NT, Yasuda S, Yasuda S, et al. Cost-effectiveness analyses of Biologic and targeted synthetic disease-modifying anti-rheumatic Diseases in patients with rheumatoid arthritis: three approaches with a cohort simulation and real-world data. Mod Rheumatol. 2022 Apr 21;33(2):302–311.
   Web of Science ®Google Scholar
• Gholami A, Azizpoor J, Aflaki E, et al. Cost-effectiveness analysis of biopharmaceuticals for treating rheumatoid arthritis: Infliximab, adalimumab, and etanercept. Bio Med Res Int. 2021;2021:1–12. doi: 10.1155/2021/4450162
   Google Scholar
• Hirose T, Kawaguchi I, Murata T, et al. Cost-effectiveness analysis of etanercept 25 mg maintenance therapy after treatment with etanercept 50 mg for moderate rheumatoid arthritis in the PRESERVE trial in Japan. Value Health Reg Issues. 2022;28:105–111. doi: 10.1016/j.vhri.2021.06.012
   PubMedGoogle Scholar
• Li SN, Li JH, Peng LB, et al. Cost-effectiveness of Baricitinib for patients with moderate-to-severe rheumatoid arthritis after methotrexate failed in China. Rheumatol Ther. 2021;8(2):863–876. doi: 10.1007/s40744-021-00308-w
   PubMed Web of Science ®Google Scholar
• Tan C, Li S, Yi L, et al. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in China: a cost-effectiveness analysis based on a mapping algorithm derived from a Chinese population. Adv Ther. 2021 May;38(5):2571–2585. doi: 10.1007/s12325-021-01733-7
   PubMed Web of Science ®Google Scholar
• Kobelt G, Lindgren P, Singh A, et al. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis. 2005 Aug;64(8):1174–1179. doi: 10.1136/ard.2004.032789
   PubMed Web of Science ®Google Scholar
• Kobelt G. Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved. Value Health. 2014 Jul;17(5):537–544. doi: 10.1016/j.jval.2014.04.005
   PubMed Web of Science ®Google Scholar